These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 35331314

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA.
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
    Spangler CJ, Yadav SP, Li D, Geil CN, Smith CB, Wang GG, Lee TH, McGinty RK.
    Cell Rep; 2022 Feb 15; 38(7):110369. PubMed ID: 35172132
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
    Banday S, Farooq Z, Ganai SA, Altaf M.
    Clin Epigenetics; 2020 May 25; 12(1):73. PubMed ID: 32450905
    [Abstract] [Full Text] [Related]

  • 8. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
    Yuan Y, Du L, Tan R, Yu Y, Jiang J, Yao A, Luo J, Tang R, Xiao Y, Sun H.
    J Med Chem; 2022 Jun 09; 65(11):7770-7785. PubMed ID: 35612819
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
    Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM.
    Blood; 2013 Aug 08; 122(6):1017-25. PubMed ID: 23801631
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT, Chen TQ, Zeng ZC, Pan Q, Huang W, Han C, Fang K, Sun LY, Yang QQ, Wang D, Luo XQ, Sun YM, Chen YQ.
    J Hematol Oncol; 2020 Jun 17; 13(1):78. PubMed ID: 32552847
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.
    Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, Daigle SR.
    Mol Cancer Ther; 2017 Aug 17; 16(8):1669-1679. PubMed ID: 28428443
    [Abstract] [Full Text] [Related]

  • 18. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
    Shen C, Jo SY, Liao C, Hess JL, Nikolovska-Coleska Z.
    J Biol Chem; 2013 Oct 18; 288(42):30585-30596. PubMed ID: 23996074
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeting epigenetic programs in MLL-rearranged leukemias.
    Bernt KM, Armstrong SA.
    Hematology Am Soc Hematol Educ Program; 2011 Oct 18; 2011():354-60. PubMed ID: 22160057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.